Approach to Thrombocytosis

Initial Diagnostic Considerations

The American Society of Hematology recommends testing for myeloproliferative neoplasm driver mutations, such as JAK2V617F, CALR, and MPL, which are present in approximately 80% of essential thrombocythemia patients in a mutually exclusive pattern 1

The American College of Physicians suggests that patients with essential thrombocythemia should be risk-stratified into four categories: very low risk, low risk, intermediate risk, and high risk, to determine treatment intensity 1
The American Heart Association recommends that patients with high-risk essential thrombocythemia should receive cytoreductive therapy, such as hydroxyurea, to reduce thrombotic events 2
The American Society of Hematology recommends that patients with extreme thrombocytosis (>1,500 × 10⁹/L) should be tested for acquired von Willebrand syndrome, as this increases bleeding risk and contraindicates aspirin 2

The American College of Cardiology recommends that patients with essential thrombocythemia should receive low-dose aspirin (81-100 mg daily) to reduce thrombosis risk, with specific modifications based on clinical context 1
The American Society of Hematology suggests that the goal of treatment is not to normalize platelet counts, but to prevent thrombosis, and that target platelet count should be individualized to reduce thrombotic risk while avoiding treatment-related complications 1

The American College of Obstetricians and Gynecologists recommends that preconceptual counseling is mandatory for patients with essential thrombocythemia, as pregnancy loss and complications are higher in this population, and that aspirin and phlebotomy should be continued throughout pregnancy 2
The American Society of Hematology recommends that patients with essential thrombocythemia should discontinue aspirin 5 days preoperatively for neurosurgery or procedures requiring complete platelet function recovery, and that platelet counts should be maintained ≥50,000/μL for major surgery 1